Cryoport CSO sells 1,341 shares for tax obligations

Cryoport, Inc. Chief Scientific Officer Mark W. Sawicki reported an automatic sale of 1,341 shares of common stock at $8.18 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Cryoport, Inc. Chief Scientific Officer Mark W. Sawicki reported an automatic sale of 1,341 shares of common stock at $8.18 per share. According to the disclosure, the shares were required to be sold under company policies to pay taxes due upon the vesting of restricted stock rights. Following this transaction, Sawicki directly holds 102,356 shares of Cryoport common stock.

Insider Trade Summary

Net Seller: 1,341 shares

Net Sell 1 txn

Insider Sawicki Mark W

Role Chief Scientific Officer

Sold 1,341 shs ($11K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,341	$8.18	$11K

Holdings After Transaction: Common Stock — 102,356 shares (Direct)

Footnotes (1)

F1. Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cryoport (CYRX) report for Mark W. Sawicki?

Cryoport reported that Chief Scientific Officer Mark W. Sawicki sold 1,341 shares of common stock at $8.18 per share. The sale was required under company policies to cover taxes triggered by the vesting of restricted stock rights, making it a tax-related, non-discretionary transaction.

Why did Cryoport (CYRX) Chief Scientific Officer sell 1,341 shares?

The 1,341 shares were sold to pay taxes due upon the vesting of restricted stock rights, as required by Cryoport’s policies. This means the transaction was executed for tax withholding purposes rather than as a discretionary open-market sale decision by the executive.

How many Cryoport (CYRX) shares does Mark W. Sawicki hold after this Form 4?

After the reported transaction, Mark W. Sawicki directly holds 102,356 shares of Cryoport common stock. This context shows the 1,341 shares sold for tax obligations represent a small portion of his overall reported equity position in the company.

Was the Cryoport (CYRX) insider sale a routine tax transaction?

Yes. The filing states the shares were “required to be sold” under the issuer’s policies to pay taxes on vesting restricted stock rights. This language indicates a routine, policy-driven tax transaction rather than a discretionary sale based on the executive’s view of Cryoport’s share price.

What type of security was involved in the Cryoport (CYRX) insider sale?

The transaction involved Cryoport common stock, with 1,341 shares sold at $8.18 per share. The sale was linked to taxes owed from the vesting of restricted stock rights, which are equity-based compensation awards that convert into common shares upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/25/2026 - 08:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sawicki Mark W

(Last)

(First)

(Middle)

C/O CRYOPORT INC.

112 WESTWOOD PLACE, SUITE 350

(Street)

BRENTWOOD

TENNESSEE

37027

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cryoport, Inc. [ CYRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/23/2026		S⁽¹⁾		1,341	D	$8.18	102,356	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.

	/s/ Mark Sawicki	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR